CSIR Ropes In Cipla To Launch Cheaper Drug For Curing Covid

Price expected to be 30% lower

- Milan Sharma

Barely a day after Indian pharma firm Glenmark Pharmaceuticals launched antiviral drug Favipiravir as FabiFlu for Covid-19 patients with mild and moderate symptoms, another multi-centre Phase-II drug trial being done by the Council of Scientific and Industrial Research (CSIR) shows that its drug can cost lesser by at least 20-30 per cent of the current price.

A source aware of the development said, Our projection is that the cost will be 20-30 per cent lesser than the current price point. As per the results, it could lead to a major reduction in the cost of the drug required for the treatment of mild and moderate symptoms of coronavirus.